Jeena Sikho Lifecare (JSLL) Q4 23/24 earnings summary

Executive summary

• FY24 audited standalone revenue from operations was ₹32,440.89 lakh and PAT was ₹6,920.63 lakh; the auditor issued an unmodified opinion.

• Revenue grew 59% YoY, EBITDA rose 102% to ₹92.99 Cr and PAT rose 105% to ₹69.21 Cr.

• Network expanded to 32 hospitals, 79 clinics and day-care centres, 1,277 operational beds, and coverage across 97 cities and 25 states.

• Operations comprise trading Ayurvedic medicines and providing Ayurvedic therapies in one operating segment.

Financial highlights

• FY24 revenue from operations was ₹32,440.89 lakh vs ₹20,389.63 lakh in FY23; total income was ₹33,084.87 lakh vs ₹20,617.88 lakh.

• FY24 PBT was ₹9,391.71 lakh vs ₹4,453.00 lakh; PAT was ₹6,920.63 lakh vs ₹3,374.44 lakh.

• H2FY24 revenue was ₹16,704.89 lakh, up 42% YoY; EBITDA was ₹48.06 Cr, up 61%, and PAT was ₹37.38 Cr, up 66%.

• FY24 gross profit was ₹292.98 Cr, up 61% YoY; gross margin increased 108 bps to 90%.

• Operating expenses were ₹199.99 Cr; EBIT was ₹87.89 Cr, up 105% YoY, and other income was ₹6.44 Cr.

Outlook and guidance

• Priorities include improving occupancy, opening new centres and adding beds at existing facilities; 15 centres were in the pipeline at different implementation stages.

• OTC pharmacy distribution is planned from H2FY25; distribution channels and strategy were under evaluation.

• Cashless treatment through empanelment with 13 insurance providers began in April 2024, with insurer and government-panel coverage targeted to expand.

• Product plans include expanding the portfolio and launching new product kits.